CPC A61K 48/005 (2013.01) [A61K 35/30 (2013.01); A61K 35/545 (2013.01); A61P 21/00 (2018.01); A61P 25/00 (2018.01); C07K 14/005 (2013.01); C12N 5/0606 (2013.01); C12N 5/0619 (2013.01); C12N 5/0667 (2013.01); C12N 5/0696 (2013.01); C12N 5/12 (2013.01); C12N 5/16 (2013.01); C12N 9/2402 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); C12N 2760/18822 (2013.01); C12N 2760/18833 (2013.01)] | 7 Claims |
1. A method of fusing stem cells or progenitor cells to damaged nerve cells, comprising:
administering stem cells or progenitor cells to the damaged nerve cells of a subject suffering from neurodegenerative diseases or neurological diseases,
wherein the stem cells or progenitor cells are transformed with a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins, and the stem cells or progenitor cells transformed with said vector express HN and F proteins and increase cell fusion with the damaged nerve cells compared to stem cells or progenitor cells not transformed with said vector.
|